Workflow
Light Delivery Device (LDD)
icon
Search documents
RXST INVESTOR NOTIFICATION: RxSight, Inc. Investors are Urged to Contact BFA Law before the September 22 Class Action Deadline (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-27 10:46
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...
RXST STOCK ALERT: RxSight, Inc. Investors may have been Affected by Fraud -- Contact BFA Law by September 22 about the Class Action (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-25 12:46
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...
RXST CLASS REMINDER: Suffer Losses on Your RxSight, Inc. Investment? Contact BFA Law before the September 22 Court Deadline (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-23 11:08
NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...
RXST DEADLINE NOTICE: RxSight, Inc. Investors are Notified of the September 22 Class Action Deadline -- Contact BFA Law if You Suffered Losses (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-21 12:18
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...
RXST Stockholders with Large Losses Should Contact Robbins LLP for Information About the RxSight, Inc. Class Action
Prnewswire· 2025-08-20 21:24
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired RxSight, Inc. (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025. RxSight is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses ("LAL") used in cataract surgery in the United States. The Company's primary product is the RxSight system ...
RXST SECURITIES: RxSight, Inc. Shareholders that Lost Money may have been Affected by Fraud -- Contact BFA Law before the Class Action Deadline (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-19 12:35
Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., and investors have until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors despite the company promoting strong sales [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines – RXST
GlobeNewswire News Room· 2025-08-17 14:27
Core Points - A class action lawsuit has been filed against RxSight, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors have until September 22, 2025, to request appointment as Lead Plaintiff if they purchased RxSight securities during the Class Period [2] - RxSight reported significant declines in Light Delivery Device sales and overall revenue, leading to a lowered full-year guidance by approximately $42.5 million [4] Financial Performance - Preliminary second quarter 2025 results showed a decline in Light Delivery Device sales and light adjustable intraocular lenses utilization [4] - Following the financial report, RxSight's stock price dropped by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [4] Legal Context - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate and securities class litigation [5] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]
RXST LOSS ALERT: RxSight, Inc. Investors with Losses are Reminded of the September 22 Class Action Deadline – Contact BFA Law (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-17 11:23
Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price, dropping approximately 38% from $26.12 to $16.21 on April 3, 2025, after cutting its 2025 revenue forecast due to a market softening noted in the second half of 2024 [5]. - Following another revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 on July 9, 2025 [6].
RXST FRAUD REMINDER: RxSight, Inc. Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law before Imminent September 22 Deadline (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-15 12:18
Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization, caused another 38% decline in stock price from $12.79 to $7.95 per share [6].
RXSIGHT STOCK: Lose Money on Your RxSight, Inc. (NASDAQ:RXST) Investment? Contact BFA Law before the September 22 Legal Deadline
GlobeNewswire News Room· 2025-08-13 12:33
Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during the relevant period [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].